Literature DB >> 22461474

Long-term results of chemoimmunotherapy with low-dose fludarabine, cyclophosphamide and high-dose rituximab as initial treatment for patients with chronic lymphocytic leukemia.

Kenneth A Foon, Dhaval Mehta, Suzanne Lentzsch, Patricia Kropf, Stanley Marks, Diana Lenzner, Louis Pietragallo, Mathew Sulecki, Ahmad Tarhini, Michael Boyiadzis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22461474     DOI： 10.1182/blood-2012-01-408047

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  11 in total

Review 1.  Initial treatment of CLL: integrating biology and functional status.

Authors:  Nitin Jain; Susan O'Brien
Journal:  Blood       Date:  2015-06-11       Impact factor: 22.113

Review 2.  The role of combined fludarabine, cyclophosphamide and rituximab chemoimmunotherapy in chronic lymphocytic leukemia: current evidence and controversies.

Authors:  Alan P Skarbnik; Stefan Faderl
Journal:  Ther Adv Hematol       Date:  2016-12-01

Review 3.  Immunotherapeutic approaches to hepatocellular carcinoma treatment.

Authors:  Alexander G Miamen; Haidong Dong; Lewis R Roberts
Journal:  Liver Cancer       Date:  2012-11       Impact factor: 11.740

Review 4.  Evolving Strategies for the Treatment of Chronic Lymphocytic Leukemia in the Upfront Setting.

Authors:  Spencer H Bachow; Nicole Lamanna
Journal:  Curr Hematol Malig Rep       Date:  2016-02       Impact factor: 3.952

5.  Impact of dose intensity on outcome of fludarabine, cyclophosphamide, and rituximab regimen given in the first-line therapy for chronic lymphocytic leukemia.

Authors:  Emmanuelle Bouvet; Cécile Borel; Lucie Obéric; Gisèle Compaci; Bruno Cazin; Anne-Sophie Michallet; Guy Laurent; Loic Ysebaert
Journal:  Haematologica       Date:  2012-10-12       Impact factor: 9.941

Review 6.  Pharmacotherapeutic Management of Chronic Lymphocytic Leukaemia in Patients with Comorbidities: New Agents, New Hope.

Authors:  Valentin Goede; Michael Hallek
Journal:  Drugs Aging       Date:  2015-11       Impact factor: 3.923

7.  ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL).

Authors:  M Ghielmini; U Vitolo; E Kimby; S Montoto; J Walewski; M Pfreundschuh; M Federico; P Hoskin; C McNamara; F Caligaris-Cappio; S Stilgenbauer; R Marcus; M Trneny; P Dreger; E Montserrat; M Dreyling
Journal:  Ann Oncol       Date:  2012-11-21       Impact factor: 32.976

Review 8.  Evolution in the management of chronic lymphocytic leukemia in Japan: should MRD negativity be the goal?

Authors:  Junji Suzumiya; Jun Takizawa
Journal:  Int J Hematol       Date:  2020-04-06       Impact factor: 2.319

Review 9.  Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience.

Authors:  Gilles Salles; Martin Barrett; Robin Foà; Joerg Maurer; Susan O'Brien; Nancy Valente; Michael Wenger; David G Maloney
Journal:  Adv Ther       Date:  2017-10-05       Impact factor: 3.845

10.  Real word evidence on rituximab utilization: Combining administrative and hospital-pharmacy data.

Authors:  Giuseppe Roberto; Andrea Spini; Claudia Bartolini; Valentino Moscatelli; Alessandro Barchielli; Davide Paoletti; Silvano Giorgi; Alberto Fabbri; Monica Bocchia; Sandra Donnini; Rosa Gini; Marina Ziche
Journal:  PLoS One       Date:  2020-03-12       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.